Index to Volume 174

Antoch J, *see* Durrieu G *et al.*
Augustin W, Wiswedel I, Noack H, Reinheckel T, Reichelt O: Role of endogenous and exogenous antioxidants in the defence against functional damage and lipid peroxidation in rat liver mitochondria 199–205

Baniene R, *see* Mildaziene V *et al.*
Bank W, Chance B: Diagnosis of defects in oxidative muscle metabolism by non-invasive tissue oximetry 7–10
Barbiroli B, Iotti S, Lodi R: *In vivo* assessment of human skeletal muscle mitochondria respiration in health and disease 11–15
Barnoux M-C, *see* Ferlin T *et al.*
Basso E, *see* Scorrano L *et al.*
Bastin ME, *see* Kemp GJ *et al.*
Becker C, *see* Löffler M *et al.*
Becker G, *see* Lindner A *et al.*
Bédes F, *see* Mazat J-P *et al.*
Bernardi P, *see* Scorrano L *et al.*
Bessman SP, Mohan C: Insulin as a probe of mitochondrial metabolism *in situ* 91–96
Bettendorff L, Goessens G, Sluse FE: Reversibility of thiamine deficiency-induced partial necrosis and mitochondrial uncoupling by addition of thiamine to neuroblastoma cell suspensions 121–124
Bezold R, *see* Hofmann S *et al.*
Biagini G, *see* Lenaz G *et al.*
Boonman AMC, *see* Scholte HR *et al.*
Bovina C, *see* Lenaz G *et al.*
Brdiczka D, *see* O'Gorman E *et al*
Brierley EJ, Johnson MA, James OFW, Turnbull DM: Mitochondrial involvement in the ageing process. Facts and controversies 325–328
Brown GC: Nitric oxide inhibition of cytochrome oxidase and mitochondrial respiration: Implications for inflammatory, neurodegenerative and ischaemic pathologies 189–192
Busch HFM, *see* Scholte HR *et al.*
Buse G, *see* Zanssen S *et al.*

Castedo M, *see* Petit PX *et al.*
Castelli GP, *see* Lenaz G *et al.*
Castelluccio C, *see* Lenaz G *et al.*
Chance B, *see* Bank W
Chretien D, *see* Rustin P *et al.*
Clark JF, *see* Kemp GJ *et al.*
Connern CP, *see* Halestrap AP *et al.*

Dagys A, *see* Toleikis A *et al.*
Daut J, *see* Köhnke D *et al.*
Deshhouillers J-M, *see* Durrieu G *et al.*
Dichgans J, *see* Schulz JB *et al.*
DiMauro S, *see* Kaufmann P *et al.*
Dörner A, Schulze K, Rauch U, Schultheiss H-P: Adenine nucleotide translocator in dilated cardiomyopathy: Pathophysiological alterations in expression and function 261–269
Dumoulin R, *see* Ferlin T *et al.*

Durrieu G, Letellier T, Antoch J, Deshouillers J-M, Malgat M, Mazat J-P: Identification of mitochondrial deficiency using principal component analysis 149–156

El-Schahawi M, *see* Kaufmann P *et al.*

Fato R, *see* Lenaz G *et al.*
Ferlin T, Guironnet G, Barnoux M-C, Dumoulin R, Stepien G, Mousson B: Detection of mitochondrial DNA deletions by a screening procedure using the polymerase chain reaction 221–225
Flint Beal M, *see* Schulz JB *et al.*
Formiggini G, *see* Lenaz G *et al.*
Frank V, *see* Kadenbach B *et al.*

Garstka HL, *see* Montoya J *et al.*
Gellerich FN, *see* Laterveer FD *et al.*
Gellerich FN, *see* Sperl W *et al.*
Gellerich JF, *see* Van Dorsten FA *et al.*
Genova ML, *see* Lenaz G *et al.*
Gerbitz K-D, *see* Hofmann S *et al.*
Gnaiger E, *see* Sperl W *et al.*
Goessens G, *see* Bettendorff L *et al.*
Griffiths EJ, *see* Halestrap AP *et al.*
Guironnet G, *see* Ferlin T *et al.*

Hager J, *see* Sperl W *et al.*
Halestrap AP, Connern CP, Griffiths EJ, Kerr PM: Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury 167–172
Hassinen IE, *see* Majamaa K *et al.*
Herman B, *see* Lemasters JJ *et al.*
Hoek JB, Walajtys-Rode E, Wang X: Hormonal stimulation, mitochondrial Ca^{2+} accumulation, and the control of the mitochondrial permeability transition in intact hepatocytes 173–179
Hofmann E, *see* Lindner A *et al.*
Hofmann S, Bezold R, Jaksch M, Kauthold P, Obermaier-Kusser B, Gerbitz K-D: Analysis of the mitochondrial DNA from patients with Wolfram (DIDMOAD) syndrome 209–213
Huizing M, *see* Trijbels FJM *et al.*

Iotti S, *see* Barbiroli B *et al.*

Jaksch M, *see* Hofmann S *et al.*
James OFW, *see* Brierley EJ *et al.*
Jeneson JAL, Wiseman RW, Kushmerick MJ: Non-invasive quantitative ^{31}P MRS assay of mitochondrial function in skeletal muscle *in situ* 17–22
Jöckel J, *see* Löffler M *et al.*
Johnson MA, *see* Brierley EJ *et al.*

Kadenbach B, Frank V, Rieger T, Napiwotzki: Regulation of respiration and energy transduction in cytochrome c oxidase isozymes by allosteric effectors 131–135
Kalvenas A, *see* Mildaziene V *et al.*
Kaufmann P, El-Schahawi M, DiMauro S: Carnitine palmitoyltransferase II deficiency: Diagnosis by molecular analysis of blood 237–239
Kaufhold P, *see* Hofmann S *et al.*
Kay L, Rossi A, Saks V: Detection of early ischemic damage by analysis of mitochondrial function in skinned fibers 79–85

Kemp GJ, Manners DN, Clark JF, Bastin ME, Radda GK: A theoretical model of some spatial and temporal aspects of the mitochondrion creatine kinase myofibril system in muscle 29–32
Kemp GJ, *see* Taylor DJ *et al.*
Kerr PM, *see* Halestrap AP *et al.*
King MP, *see* Masucci JP *et al.*
Kirches E, *see* Kunz WS *et al.*
Klockgether T, *see* Schulz JB *et al.*
Köhnke D, Schramm M, Daut J: Oxidative phosphorylation in myocardial mitochondria '*in situ*': A calorimetric study on permeabilized cardiac muscle preparations 101–113
Klopstock T, Naumann M, Seibel P, Schalke B, Reiners K, Reichmann H: Mitochondrial DNA mutations in multiple symmetric lipomatosis 271–275
Korzeniewski B: Thermodynamic regulation of cytochrome oxidase 137–141
Korzeniewski B, *see* Mazat J-P *et al.*
Kroemer G, *see* Petit PX *et al.*
Kunz WS, Winkler K, Kuznetsov AV, Lins H, Kirches E, Wallesch CW: Detection of mitochondrial defects by laser fluorimetry 97–100
Kushmerick MJ, *see* Jeneson JAL *et al.*
Kushmerick MJ, *see* Wiseman RW
Kuznetsov AV, *see* Kunz WS *et al.*

Laterveer FD, Nicolay K, Gellerich FN: Experimental evidence for dynamic compartmentation of ADP at the mitochondrial periphery: Coupling of mitochondrial adenylate kinase and mitochondrial hexokinase with oxidative phosphorylation under conditions mimicking the intracellular colloid osmotic pressure 43–51
Lemasters JJ, Nieminen A-L, Qian T, Trost LC, Herman B: The mitochondrial permeability transition in toxic, hypoxic and reperfusion injury 159–165
Lenaz G, Bovina C, Castelluccio C, Fato R, Formiggini G, Genova ML, Marchetti M, Pich MM, Pallotti F, Castelli GP, Biagini: Mitochondrial Complex I defects in aging 329–333
Letellier T, *see* Durrieu *et al.*
Letellier T, *see* Mazat J-P *et al.*
Lindner A, Hofmann E, Naumann M, Becker G, Reichmann H: Clinical, morphological, biochemical, and neuroradiological features of mitochondrial encephalomyopathies. Presentation of 19 patients 297–303
Lins H, *see* Kunz WS *et al.*
Lodi R, *see* Barbiroli B *et al.*
Löffler M, Jöckel J, Schuster G, Becker C: Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides 125–129
Ludolph, AC, *see* Riepe MW

Majamaa K, Rusanen H, Remes A, Hassinen IE: Metabolic interventions against complex I deficiency in MELAS syndrome 291–296
Majiene D, *see* Toleikis A *et al.*
Malgat M, *see* Durrieu G *et al.*
Malgat M, *see* Mazat J-P *et al.*
Manners DN, *see* Kemp GJ *et al.*
Marchetti M, *see* Lenaz G *et al.*
Marcinkeviciute A, *see* Mildaziene V *et al.*
Masucci JP, Schon EA, King MP: Point mutations in the mitochondrial $tRNA^{Lys}$ gene: Implications for pathogenesis and mechanism 215–219
Matthews RT, *see* Schulz JB *et al.*
Maurer I, Möller H-J: Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics 255–259
Mayr U, *see* Sperl W *et al.*
Mazat J-P, Letellier T, Bédes F, Malgat M, Korzeniewski B, Jouaville LS, Morkuniene R: Metabolic control analysis and threshold effect in oxidative phosphorylation: Implications for mitochondrial pathologies 143–148

Mazat J-P, *see* Durrieu G *et al.*
Mignotte B, *see* Petit PX *et al.*
Mildaziene V, Baniene R, Marcinkeviciute A, Nauciene Z, Kalvenas A, Zimkus A: Tetraphenylphosphonium inhibits oxidation of physiological substrates in heart mitochondria 67–70
Möller H-J, *see* Maurer I
Mohan C, *see* Bessman SP
Molnar M, *see* Schröder JM
Molnar M, *see* Zanssen S *et al.*
Montoya J, Garstka HL, Perez-Martos A, Wiesner RJ: Regulation of mitochondrial transcription by mitochondrial transcription factor A 227–230
Mousson B, *see* Ferlin T *et al.*
Muller H-J, *see* Van Dorsten FA *et al.*
Müller M, *see* O'Gorman E *et al.*
Munnich A, *see* Rustin P *et al.*

Napiwotzki J, *see* Kadenbach B *et al.*
Nauciene Z, *see* Mildaziene V *et al.*
Naumann M, *see* Klopstock T *et al.*
Naumann M *see* Lindner A *et al.*
Nederhoff MGJ, *see* Van Dorsten FA *et al.*
Nicolay K, *see* Laterveer FD *et al.*
Nicolay K, *see* Van Dorsten FA *et al.*
Nicolli A, *see* Scorrano L *et al.*
Nieminen A-L, *see* Lemasters JJ *et al.*
Noack H, *see* Augustin W *et al.*

Obermaier-Kusser B, *see* Hofmann S *et al.*
O'Gorman E, Piendl T, Müller M, Brdiczka D, Wallimann T: Mitochondrial intermembrane inclusion bodies: The common denominator between human mitochondrial myopathies and creatine depletion, due to impairment of cellular energetics 283–289
Oosterkamp II, *see* Scholte HR *et al.*

Pallotti F, *see* Lenaz G *et al.*
Papa S, Skulachev VP: Reactive oxygen species, mitochondria, apoptosis and aging 305–319
Parfait B, *see* Rustin P *et al.*
Perez-Martos A, *see* Montoya J *et al.*
Petit PX, Zamzami N, Vayssière J-L, Mignotte B, Kroemer G, Castedo M: Implication of mitochondria in apoptosis 185–188
Petronilli V, *see* Scorrano L *et al.*
Pich MM, *see* Lenaz G *et al.*
Piendl T, *see* O'Gorman E *et al.*

Qian T, *see* Lemasters JJ *et al.*

Radda GK, *see* Kemp GJ *et al.*
Radda GK, *see* Taylor DJ *et al.*
Rasmussen HN, Rasmussen UF: Small scale preparation of skeletal muscle mitochondria, criteria of integrity, and assays with reference to tissue function 55–60
Rasmussen UF, *see* Rasmussen HN
Rauch U, *see* Dörner A *et al.*
Reese T, *see* Van Dorsten FA *et al.*
Reichelt O, *see* Augustin W *et al.*
Reichmann H, *see* Klopstock T *et al.*
Reichmann H, *see* Lindner A *et al.*

Reiners K, *see* Klopstock T *et al.*
Reinheckel T, *see* Augustin W *et al.*
Remes A, *see* Majamaa K *et al.*
Rieger T, *see* Kadenbach B *et al.*
Riepe MW, Ludolph AC: Chemical preconditioning: A cytoprotective strategy 249–254
Rötig A, *see* Rustin P *et al.*
Ross JD, *see* Scholte HR *et al.*
Rossi A, *see* Kay L *et al.*
Ruitenbeek W, *see* Trijbels FJM *et al.*
Rusanen H, *see* Majamaa K *et al.*
Rustin P, Chretien D, Parfait B, Rötig A, Munnich A: Nicotinamide adenine dinucleotides permeate through mitochondrial membranes in human Epstein-Barr virus-transformed lymphocytes 115–119

Saks V, *see* Kay L *et al.*
Schalke B, *see* Klopsock T *et al.*
Scholte HR, Yu Y, Ross JD, Oosterkamp II, Boonman AMC, Busch HFM: Rapid isolation of muscle and heart mitochondria, the lability of oxidative phosphorylation and attempts to stabilize the process *in vitro* by taurine, carnitine and other compounds 61–66
Schon EA, *see* Masucci JP *et al.*
Schramm M, *see* Köhnke D *et al.*
Schröder JM, Molnar M: Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion body myositis 277–281
Schröder JM, *see* Zanssen S *et al.*
Schultheiss H-P, *see* Dörner A *et al.*
Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF: The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases 193–197
Schulze K, *see* Dörner A *et al.*
Schuster G, *see* Löffler M *et al.*
Scorrano L, Nicolli A, Basso E, Petronilli V, Bernardi P: Two modes of activation of the permeability transition pore: The role of mitochondrial cyclophilin 181–184
Seibel P, *see* Klopstock T *et al.*
Sengers RCA, *see* Trijbels FJM *et al.*
Skladal D, *see* Sperl W *et al.*
Skulachev VP, *see* Papa S
Sluse FE, *see* Bettendorff L *et al.*
Smeitink JAM, *see* Trijbels FJM *et al.*
Sperl W, Skladal D, Gnaiger E, Wyss M, Mayr U, Hager J, Gellerich FN: High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders 71–78
Stepien G, *see* Ferlin T *et al.*

Taylor DJ, Kemp GJ, Thompson CH, Radda GK: Ageing: Effects on oxidative function of skeletal muscle *in vivo* 321–324
Thompson CH, *see* Taylor DJ *et al.*
Toleikis A, Majiene D, Trumbeckaite S, Dagys A: The effects of ischemia and experimental conditions on the respiration rate of cardiac fibers 87–90
Trijbels FJM, Ruitenbeek W, Huizing M, Wendel U, Smeitink JAM, Sengers RCA: Defects in the mitochondrial energy metabolism outside the respiratory chain and the pyruvate dehydrogenase complex 243–247
Trost LC *see* Lemasters JJ *et al.*
Trumbeckaite S, *see* Toleikis A *et al.*
Turnbull DM, *see* Brierley EJ *et al.*

Van Dorsten FA, Reese T, Gellerich JF, Van Echteld CJA, Nederhoff, MGJ, Muller H-J, Van Vliet G, Nicolay K: Fluxes through cytosolic and mitochondrial creatine kinase, measured by P-31 NMR 33–42
Van Echteld CJA, *see* Van Dorsten FA *et al.*

Van Vliet G, *see* Van Dorsten FA *et al.*
Vayssière J-L, *see* Petit PX *et al.*

Walajtys-Rode E, *see* Hoek JB *et al.*
Walles CW, *see* Kunz WS *et al.*
Walliman T, *see* O'Gorman E *et al.*
Wang X, *see* Hoek JB *et al.*
Wendel U, *see* Trijbels FJM *et al.*
Wiesner RJ, *see* Montoya J *et al.*
Winkler K, *see* Kunz WS *et al.*
Wiseman RW, Kushmerick MJ: Phosphorus metabolite distribution in skeletal muscle: Quantitative bioenergetics using creatine analogs 23–28
Wiseman RM, *see* Jeneson JAL *et al.*
Wiswedel I, *see* Augustin W *et al.*
Wyss M, *see* Sperl W *et al.*

Yu Y, *see* Scholte HR *et al.*

Zamzani N, *see* Petit PX *et al.*
Zanssen S, Molnar M, Schröder JM, Buse G: Multiple mitochondrial $tRNA^{Leu[UUR]}$ mutations associated with infantile myopathy 231–236
Zimkus A, *see* Mildaziene V *et al.*